Aptevo Therapeutics Reports $6.7 Million Net Loss in Q1 2026, Faces Funding Challenges

Aptevo Therapeutics Inc. reported a net loss of $6.7 million for the first quarter of 2026, compared to a loss of $6.4 million during the same period in 2025. The company's total operating expenses increased to $6.8 million, up from $6.5 million year-over-year, primarily driven by higher research and development costs, which rose to $3.9 million from $3.6 million. The increase in R&D expenses was attributed to higher costs associated with the clinical candidate mipletamig, while expenses for ALG.APV-527 decreased as the dose escalation trial concluded. The company ended the quarter with cash and cash equivalents of $14.5 million, down from $21.6 million at the end of 2025.

In terms of strategic developments, Aptevo has made significant progress in its clinical programs. The ongoing RAINIER trial for mipletamig, a CD123xCD3 T cell engager, is on track for completion and Phase 2 dose selection by the end of 2026. The trial has shown promising results, with an 87% clinical benefit rate and 65% of patients achieving complete remission. Additionally, the company has undergone leadership changes, appointing Jeff Lamothe as President and CEO, while Marvin White transitioned to Executive Chair, aiming to enhance strategic execution across clinical development and capital strategy.

Operationally, Aptevo's total assets decreased to $19.9 million as of March 31, 2026, down from $27.2 million at the end of 2025. The company’s stockholders' equity also fell to $11.6 million from $17.4 million, reflecting the ongoing losses and capital needs. Aptevo has raised approximately $0.9 million through Standby Equity Purchase Agreements (SEPAs) with Yorkville, which provide access to additional capital. The company has a remaining availability of $67.2 million under its SEPAs, which it plans to utilize to support ongoing development programs.

Looking ahead, Aptevo faces substantial challenges, including the need for additional funding to support its clinical trials and operational expenses. The company has expressed concerns about its ability to continue as a going concern, given its history of losses and the need for further capital to sustain operations. Management anticipates that it will continue to incur significant operating losses as it advances its product candidates through clinical development. The company is actively exploring various financing options, including potential collaborations and licensing arrangements, to secure the necessary funds for its ongoing and future projects.